Healthy volunteers E71.3
Conditions
Interventions
Group 1: Arm 1 = X-ALD patients with the non-inflammatory X-ALD form
Using plasma and serum remnant samples derived from clinical routine examinations, we will perform 2 independent investigations: 1
Sponsors
Center for Brain Research, Medical University of Vienna
Eligibility
Sex/Gender
All
Age
3 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for plasma/serum remnant samples from X-ALD patients are: 1) diagnosis of X-ALD by measurement of very long-chain fatty acids in the blood 2) patient details (sex and age) are known at time of blood donation 3) available data on the clinical course of the disease 4) knowledge on medication and supplementation of the patient Inclusion criteria for plasma/serum remnant samples from healthy controls are: 1) patient details (sex and age) are known at time of blood donation 2) no diagnosis of X-ALD or other disorders associated with neurodegeneration or neuroinflammation
Exclusion criteria
Exclusion criteria: Exclusion criteria for plasma/serum remnant samples from X-ALD patients and controls are: Intake of lipid lowering and anti-inflammatory medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints of this study are the blood level of neurofilament light chain protein and the epigenetic status of cell free DNA isolated from the plasma. The primary endpoints will be determined by single molecule array (SiMoA) technique and next generation sequencing. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint of this study is whether the identified differences in the amount of neurofilament light chain protein and epigenetic status of cell free DNA correlate with the progression of AMN and/or CALD. | — |
Countries
Austria, Germany
Contacts
Public ContactIsabelle Weinhofer
Zentrum für Hirnforschung, Medizinische Universität Wien
Outcome results
None listed